AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10737578
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection in the internal anal sphincter on each side of the anterior midline (group II)
Trial: 8725483
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (medication)
Trial: 12674130
Drug: Estrogen-progestin hormone
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestin hormone replacement therapy
Trial: 1328978
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who had never taken hormone replacement therapy
Trial: 1328978
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who had ever taken hormone replacement therapy
Trial: 21159397
Drug: Treatment times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment times
Trial: 15730803
Drug: Normal internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal internal medicine treatments (Control)
Trial: 7931752
Drug: Physicians prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians prescribing medications
Trial: 3652706
Drug: Surfactant (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (2 ml/kg; phospholipid concentration, 100 mg/ml) administered via naso-endotracheal tube during standardized ventilatory maneuvers
Trial: 28865459
Drug: Indigo naturalis
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigo naturalis ointment (n = 16)
Trial: 19688315
Drug: Qingre Buyi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Buyi Decoction (QBD) plus conventional treatment
Trial: 14742998
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1 g every 8 hr) from days 15 to 100 after transplantation
Trial: 14742998
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (6 mg/kg once per day on Monday‐Friday of each week) from days 15 to 100 after transplantation
Trial: 2404346
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg at night)
Trial: 29773490
Drug: VSM arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VSM arm (study website with vaccine information and social media components)
Trial: 29773490
Drug: VI arm
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VI arm (website with vaccine information only)
Trial: 29773490
Drug: Self-efficacy around
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-efficacy around vaccine decision making
Trial: 24415868
Drug: CIGB-230 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIGB-230 (6 doses as late add-on)
Trial: 23111478
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy for 6 months
Trial: 18403419
Drug: Flare-up GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flare-up GnRH agonist protocol
Trial: 12459133
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education (verbal and written information on generic vs brand-name drugs)
Trial: 8583018
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine rinse, 18 mg per rinse
Trial: 8583018
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine rinse, 20 mg per rinse
Trial: 2127178
Drug: Glibenclamid‐ratiopharm (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamid‐ratiopharm (treatment A)
Trial: 2127178
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (treatment B)
Trial: 6117901
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prostacyclin (PGI2) and heparin
Trial: 26023778
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose booster regimen of OCV (n = 184)
Trial: 26023778
Drug: Single boosting
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single boosting dose of OCV
Trial: 26023778
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose primary series of OCV (n = 186)
Trial: 21640866
Drug: 1% casein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) solution
Trial: 16708532
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg slow release)
Trial: 15270791
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of questionnaire and FPG
Trial: 9550641
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg o.d. (slow release formulation) for 1 week
Trial: 2903386
Drug: Oral co‐trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co‐trimoxazole for 5 days
Trial: 2903386
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular dose of fortified procaine penicillin and 5 days of oral ampicillin
Trial: 19572180
Drug: Both 585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 585 nm and 595 nm PDL treatments
Trial: 10895201
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m2 IV bolus) followed one hour later by Taxotere (60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles)
Trial: 8831596
Drug: Intravenous cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefotaxime
Trial: 1578593
Drug: Buprenorphine, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine, 8 mg/d
Trial: 1578593
Drug: Methadone, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone, 60 mg/d
Trial: 1578593
Drug: Methadone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone, 20 mg/d
Trial: 28451529
Drug: Strengthened self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthened self-management program guidance (including seven modules: disease knowledge, breathing exercises, emotion management, home oxygen therapy, medicine intake technique, healthy life behaviors, action plans in deterioration stage)
Trial: 17242627
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 or 6 mg depending on body weight)
Trial: 11736864
Drug: Six drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, chlorzoxazone 250 mg, diclofenac 25 mg, MDZ 5 mg)
Trial: 11736864
Drug: Five drug
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, diclofenac 50 mg, without chlorzoxazone)
Trial: 11736864
Drug: Six drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six drug cocktail (as above with chlorzoxazone)
Trial: 9431858
Drug: Lacidipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (2 mg once daily)
Trial: 9431858
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg once daily)
Trial: 8305770
Drug: Mylan's MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylan's MTX tablets (15 mg administered as six 2.5-mg tablets)
Trial: 8305770
Drug: Lederle's MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle's MTX tablets (15 mg administered as six 2.5-mg tablets)
Trial: 3790405
Drug: Anticholinergic drugs
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drugs (Atropine and Glycopyrrolate)
Trial: 31574025
Drug: Bleomycin injection
RxNorm normalized name: bleomycin Injection
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleomycin injection
Trial: 23530962
Drug: Full mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full mouth periodontal treatment with an ultrasonic device and supragingival plaque control
Trial: 21784145
Drug: n-3 supplementation
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 supplementation (2.5 g/d, 2085 mg eicosapentaenoic acid and 348 mg docosahexanoic acid)
Trial: 16751617
Drug: Hypertonic-hyperoncotic solution
RxNorm normalized name: Hypertonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic-hyperoncotic solution (Poly-(O-2)-hydroxyethyl-starch 60.0 g, Na+ 1232 mmol/L, osmolality 2464 mOsmol/L)
Trial: 16758849
Drug: Hypertonic-hyperoncotic solution
RxNorm normalized name: Hypertonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic-hyperoncotic solution
Trial: 16751617
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (0.9% sodium chloride)
Trial: 11220717
Drug: Omeprazole therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole therapy (40 or 60 mg daily as needed)
Trial: 7931474
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A (100,000 IU/d) for 18 months
Trial: 3229297
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg L-acetylcarnitine
Trial: 3229297
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg L-acetylcarnitine
Trial: 3229297
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg L-acetylcarnitine
Trial: 21982758
Drug: 1 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/min O(2) via a demand system during sleep (n = 3)
Trial: 21982758
Drug: 1 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4)
Trial: 21982758
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg acetazolamide 30 minutes before bedtime (n = 4)
Trial: 18781275
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) 5 mg/kg over 24 h
Trial: 12854104
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Trial: 12854104
Drug: Monotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (standard peripheral intravenous nutrition with topical GTN only)
Trial: 12854104
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Trial: 6103299
Drug: Oral diethylcarbamazine
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral diethylcarbamazine citrate (DEC)
Trial: 7020746
Drug: Topical diethylcarbamazine
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical diethylcarbamazine (DEC) lotion
Trial: 6103299
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and topical DEC)
Trial: 31820059
Drug: Topical insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin (30 International Units Insulin Regular in 30 ml of normal saline)
Trial: 25459392
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) at a dosage of 1.000mg/m² d1, 8, 15 q28
Trial: 21959870
Drug: Epoetin-β (EPO)
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-β (EPO) 36,000 IU weekly for 12 weeks
Trial: 11102251
Drug: Lanoteplase 120
RxNorm normalized name: Lanoteplase
DrugBank: Lanoteplase (DB06245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoteplase 120 KU/kg as a single intravenous bolus
Trial: 11102251
Drug: Accelerated alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated alteplase up to 100 mg given over 90 min
Trial: 9470884
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patch (24 hour transdermal nicotine patch over a 10 week course)
Trial: 7958544
Drug: Monomeric insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monomeric insulin analogue [Lys(B28),Pro(B29)] (MI)
Trial: 2884796
Drug: atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.5 mg X kg‐1
Trial: 2884796
Drug: pipecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pipecuronium 0.1 mg X kg‐1
Trial: 2884796
Drug: vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.1 mg X kg‐1
Trial: 26563915
Drug: Vitamin D-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-containing supplements ≥3 days/week
Trial: 12627405
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment method based on joint toxicity and efficacy
Trial: 19458926
Drug: Baclofen 60
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 60 mg/day
Trial: 22540412
Drug: Platform-switched implants
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched implants (mismatch 0.35-0.40 mm)
Trial: 22540412
Drug: Conventional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implants (control)
Trial: 20730060
Drug: Valsartan 40
RxNorm normalized name: valsartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 40 mg bid (n = 60)
Trial: 20730060
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg qd (n = 55)
Trial: 20730060
Drug: Valsartan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (both dosing regimens)
Trial: 16183682
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.125% with fentanyl 3 microg ml(‐1)
Trial: 16183682
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.125% with clonidine 0.6 microg ml(‐1)
Trial: 12861131
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d for 13 days every 3 months)
Trial: 1387806
Drug: Initial empirical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial empirical regimen with antibiotics active against gram-positive organisms
Trial: 30113522
Drug: whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: whey protein (25 g) plus HMB (1.5 g)
Trial: 30113522
Drug: whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: whey protein (25 g) plus leucine (1.5 g)
Trial: 24584876
Drug: Standard doxorubicin-cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doxorubicin-cyclophosphamide followed by paclitaxel with bevacizumab therapy (duration not specified)
Trial: 22965699
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine combined with Chinese medicine (CM) treatment
Trial: 22965699
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Amlodipine Besylate Tablets and Irbesartan Tablets or Irbesartan and Hydrochlorothiazide Tablets)
Trial: 18845709
Drug: Single PS
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single PS dose consumed as an afternoon snack (1.6 g/d)
Trial: 18845709
Drug: Single PS
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single PS dose consumed with a meal (1.6 g/d)
Trial: 18845709
Drug: Single PS
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single PS dose consumed as an afternoon snack
Trial: 18845709
Drug: Single PS
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single PS dose consumed with a meal
Trial: 16150741
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention (diagnostic and treatment algorithm, small group sessions, videotapes, written material, outreach visits, one-on-one interviews with physicians)
Trial: 10202165
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m² per week for six weeks (group 1)
Trial: 10202165
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m² on days 1 and 29, 4 g of fluorouracil per m² as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea twice weekly for six weeks (group 2)
Trial: 10202165
Drug: Hydroxyurea 3
RxNorm normalized name: hydroxyurea 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea 3 g/m² twice weekly for six weeks (group 3)
Trial: 7869476
Drug: Indoramin (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (alpha 1‐adrenergic receptor antagonist)
Trial: 2611090
Drug: Aspirin 1.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1.95 g day‐1 for 1 week
Trial: 2611090
Drug: Aspirin 3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 3.25 g day‐1 for 1 week
Trial: 2611090
Drug: Aspirin 4.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 4.55 g day‐1 for 1 week
Trial: 2611090
Drug: Aspirin 5.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 5.85 g day‐1 for 1 week
Trial: 25451428
Drug: Psychoeducational family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational family intervention (PFI) and Treatment As Usual (TAU)
Trial: 23553151
Drug: Flavonoid-enriched chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-enriched chocolate (27 g/d; 850 mg flavan-3-ols + 100 mg isoflavones)
Trial: 22162988
Drug: Strategy A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy A (two standard doses over 28 days)
Trial: 22162988
Drug: Strategy B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy B (two double doses over 28 days)
Trial: 22162988
Drug: Strategy C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy C (single standard dose of influenza vaccine)
Trial: 22162988
Drug: Strategy D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy D (previous year's standard-dose vaccination)
Trial: 18085694
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg/day
Trial: 16282339
Drug: Acyclovir 800
RxNorm normalized name: acyclovir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 800 mg twice daily
Trial: 10922130
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day for 7 days
Trial: 1329618
Drug: Rufloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin 400 mg loading dose followed by 200 mg daily for 9 days
Trial: 1329618
Drug: Rufloxacin 600
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rufloxacin 600 mg loading dose followed by 300 mg daily for 9 days
Trial: 4019262
Drug: Riboflavin plus
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin plus iron supplements
Trial: 17965424
Drug: etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg daily
Trial: 17965424
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg twice daily